Milk derived primary Mammary Epithelial Cells (pMECs) are potential tools in pursuit of future scientific breakthrough as they represent 90% of in-vivo environment as compared to transformed cells. Lack of commercial availability of pMECs is a problem faced by scientific community. Additionally longevity and viability of pMECs to undergo a set of experiments on an identical genotypic culture of primary cells, is a problem often recognized by scientists and industry while doing R&D for vaccine production etc. As per global report, primary cells market is expected to grow at a CAGR of 8.5% from 2018-2023 and Asian countries are the focus of this market growth.1 Present technology offers itself as an opportunity for tapping the potential market and meeting pMECs needs of innovators.

Read Full Details